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Abstract
Background: Ventricular tachycardia (VT) can persist following placement of a left ventricular assist device (LVAD).
The optimal management strategy for VT during the peri-LVAD period is unknown.
Case Presentations: Two case reports are presented that describe epicardial and endocardial VT ablation
performed during LVAD placement. Subsequently, both patients developed LVAD thrombosis, a known and
dreaded complication of LVADs, requiring re-operation.
Conclusions: While LVAD thrombosis is likely multifactorial and remains an area of active research, these two cases
should increase awareness of the possible risks of VT ablation—especially endocardial ablation—during LVAD
placement. Further research is needed to understand the effects of VT ablation during the peri-LVAD period.
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Background
Left ventricular assist devices (LVADs) have the potential
to improve survival and quality of life, yet complications
are common—including ventricular tachycardia (VT)
[1]. The ideal management strategy for VT peri-LVAD
placement is unknown; however, there are isolated
reports of performing concomitant surgical VT cryoabla-
tion at the time of LVAD placement with successful
reduction in arrhythmia burden [2, 3]. In theory, there
are advantages to performing such an open surgical
ablation compared to percutaneous catheter based
approaches including the ability to fully visualize the
epicardial surface and left ventricular (LV) endocardium
through the ventriculotomy that is required for LVAD
inflow cannula placement. Herein, we present two cases
of concomitant surgical epicardial and endocardial VT
cryoablation prior to LVAD placement that resulted in
successful treatment of VT, but were complicated by
subsequent LVAD pump thrombosis (Table 1).
Case Presentation
Case 1
A 70-year-old female with non-ischemic cardiomyopathy
presented in cardiogenic shock with incessant mono-
morphic VT that required intravenous (IV) lidocaine
and amiodarone to remain quiescent. Given her
hemodynamics, an intra-aortic balloon pump was
placed. She was stabilized over several days and was
taken to the operating room where she underwent an
open epicardial and endocardial VT ablation with cryo-
probe. Pace activation mapping of the LV was performed
until the patient’s morphologic VT was identified on the
anterior lateral wall. Cryoablation at this site suppressed
further VT development. Additional endocardial and
epicardial ablation lines were performed to isolate the
multiple areas of scar throughout the LV. This was
followed by implantation of a HeartMate II (Thoratec,
Pleasanton, CA) LVAD as destination therapy. Post-
operatively, the patient was maintained on oral
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amiodarone, anticoagulated per guidelines with IV hep-
arin, started on aspirin 81 mg daily and warfarin with a
goal INR of 2.0–3.0. She had no sustained VT post-
LVAD; however her lactate dehydrogenase (LDH) slowly
rose to approximately two times the upper limit of nor-
mal. At this time, she had no obvious evidence of LVAD
malfunction with a normal ramp echocardiogram and
right heart catheterization confirming low left sided fill-
ing pressures and a cardiac output that matched the flow
of the LVAD controller. Thus, she was subsequently dis-
charged 4 weeks after implant. She presented 2 months
later with an LDH seven times the upper limit of nor-
mal, hematuria, and heart failure symptoms. The patient
underwent emergent device exchange for pump throm-
bosis and was discharged after a 3 week hospital stay.
There was no evidence of thrombus in the LV cavity;
however, examination of the explanted pump revealed a
denatured thrombus ring adhered to the inlet bearing
cup. Thirteen months later, she has not had any recur-
rence of sustained VT.
Case 2
A 64-year-old male with ischemic cardiomyopathy was
admitted with recurrent VT despite failing multiple oral
antiarrhythmic medications. The patient was referred for
percutaneous VT ablation; however, after induction of
VT during the procedure, the patient arrested, required
cardiopulmonary resuscitation, and was placed on veno-
arterial extracorporeal membrane oxygenation. Intraven-
ous amiodarone was initiated, and after several days of
stabilization in the intensive care unit, the patient under-
went open epicardial and endocardial VT ablation
with cryoprobe. Pace activation mapping of the LV
was performed and revealed that the patient’s
morphologic VT came from an area near the LV
septum, which was isolated with a circular cryoabla-
tion line. The patient’s VT was still inducible so
several additional endocardial and epicardial ablation
lines were required to terminate the patient’s VT.
This was followed by implantation of a HeartMate II
LVAD as bridge to transplant. Post-operatively, the
patient was maintained on oral amiodarone and mexi-
letine with no further VT. He was anticoagulated per
guidelines with IV heparin and received aspirin
81 mg daily and warfarin with a goal INR of 2.0–3.0.
On post-implant day 18, the patient’s LDH started to
slowly rise with a peak greater than five times the
upper limit of normal. At post-implant day 20, he
developed hematuria and acute renal failure and
underwent emergent device exchange for device
thrombosis. There was no evidence of thrombus in
the LV cavity; however, there was confirmed thrombus
on the pump rotor. The patient was discharged to
acute rehab 4 weeks after device exchange. Nine
months later, the patient is doing well and is free of
any further VT.
Discussion
In both cases, patients underwent open surgical
cryoablation at the time of LVAD implantation and
subsequently developed LVAD thrombosis. Cryoabla-
tion during LVAD implantation has been reported to
decrease post-operative ventricular arrhythmias in
select patients without an increase in the rate of
adverse events [2–4]. However, several of these reports
were published prior to the heightened awareness of
thrombosis risk generated from more recent publications
regarding LVAD pump thrombosis [5]. The etiology and
risk factors for LVAD thrombosis remain an area of active
investigation and is likely multifactorial.
While it is possible that other factors contributed to
thrombosis in these patients, the likely association between
the ablation procedures—specifically the LV endocardial
ablation prior to LVAD inflow cannula placement—has a
theoretical basis that deserves additional attention. First,
ablation has been associated with an overall pro-
inflammatory and thrombogenic state [6]. Second, it is also
possible that the LV endocardial surface is more prone to
thrombus formation related to inflammation and injury
Table 1 Patient characteristics





















Anticoagulation Heparin Warfarina Heparin Warfarina
Aspirin 81 mg 81 mg
Peak LDHb 2086 U/L 1368 U/L




aInternational normalized ratio goal 2.0-3.0
bNormal lab value 124–271 U/L
bpm beats per minute, LDH lactate dehydrogenase, LVAD left ventricular assist
device, VT ventricular tachycardia
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that results from the ablation itself. Finally, there are alter-
ations in blood flow patterns within the LV related to flow
into the LVAD inflow cannula that can result in low-flow
stasis within certain portions of the LV cavity (e.g. due to
the cannula position, the LV apex does not fully contract
causing blood to pool). The combination of these three
factors—thrombogenic state, endocardial inflammation,
and stasis—are well known to be associated with thrombus
formation [4]. Based on these factors, it may be reasonable
to limit open surgical VT cryoablation to only epicardial
ablation during LVAD placement.
Conclusion
Given the substantial morbidity and risk for mortality
with LVAD thrombosis and the continued uncertainty
regarding mechanisms, these cases illustrate the com-
plex patient factors that may contribute to this dreaded
complication. Clinicians should be aware of the potential
negative consequences of endocardial ablation at the
time of LVAD placement. Further research (including
the safety of isolated epicardial cryoablation without LV
involvement) in the pre-operative management of VT in
this population is warranted. In addition, larger multi-
institutional LVAD studies are needed to confirm
whether similar findings are present in a much broader
cohort of patients.
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